Obesity / Overweight – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of obesity / overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of obesity / overweight for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s obesity / overweight forecast will answer the following questions:

• Of all people with obesity / overweight, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of obesity / overweight over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts 11 obesity / overweight patient populations, as follows:

• Diagnosed prevalent cases of obesity / overweight.
• Undiagnosed prevalent cases of obesity / overweight.
• Total prevalent cases of obesity.
• Total prevalent cases of class I obesity.
• Total prevalent cases of class II obesity.
• Total prevalent cases of class III obesity.
• Total prevalent cases of overweight.
• Total obesity prevalent cases after effective usage of GLP-1 RAs.
• Drug-treatable prevalent cases of overweight.
• Diagnosed drug-treated prevalent cases of obesity.
• Diagnosed non-drug-treated prevalent cases of obesity.

Note: Coverage may vary by country.